NEW YORK (GenomeWeb) – Luminex said today that the US Food and Drug Administration has given 510(k) clearance for the firm's Aries C. difficile assay — a moderate complexity, sample-to-answer test for rapid detection of Clostridium difficile, which has become a common microbial cause of healthcare-associated infections in US hospitals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.